|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
12
|
|
pubmed:dateCreated |
2006-11-19
|
|
pubmed:abstractText |
There is growing evidence from in vitro studies that subgroup B adenoviruses (Ad) can overcome the limitations in safety and tumor transduction efficiency seen with commonly used subgroup C serotype 5-based vectors. In this study, we confirm that the expression level of the B-group Ad receptor, CD46, correlates with the grade of malignancy of cervical cancer in situ. We also demonstrate the in vivo properties of Ad5-based vectors that contain the B-group Ad serotype 35 fiber (Ad5/35) in transgenic mice that express CD46 in a pattern and at a level similar to humans. Upon intravenous and intraperitoneal injection, an Ad5/35 vector did not efficiently transduce normal tissue, but was able to target metastatic or intraperitoneal tumors that express CD46 at levels comparable to human tumors. When an oncolytic Ad5/35-based vector was employed, in both tumor models antitumor effects were observed. Furthermore, injection of Ad5/35 vectors into CD46 transgenic mice caused less innate toxicity than Ad5 vectors. Our data demonstrate that Ad vectors that target CD46 offer advantages over Ad5-based vectors for treatment of cancer.
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Dec
|
|
pubmed:issn |
0929-1903
|
|
pubmed:author |
pubmed-author:Di PaoloNN,
pubmed-author:DickM WMW,
pubmed-author:GaggarAA,
pubmed-author:KiviatNN,
pubmed-author:LiZ YZY,
pubmed-author:LieII,
pubmed-author:LieberAA,
pubmed-author:MoJJ,
pubmed-author:MoriharaJJ,
pubmed-author:ROHNH LHL,
pubmed-author:StraussRR,
pubmed-author:TouréPP,
pubmed-author:VozM LML
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
13
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1072-81
|
|
pubmed:dateRevised |
2007-11-14
|
|
pubmed:meshHeading |
pubmed-meshheading:16874361-Adenoviridae,
pubmed-meshheading:16874361-Animals,
pubmed-meshheading:16874361-Antigens, CD46,
pubmed-meshheading:16874361-Cell Line, Tumor,
pubmed-meshheading:16874361-Chemokines,
pubmed-meshheading:16874361-CpG Islands,
pubmed-meshheading:16874361-Cytokines,
pubmed-meshheading:16874361-DNA Methylation,
pubmed-meshheading:16874361-Female,
pubmed-meshheading:16874361-Gene Therapy,
pubmed-meshheading:16874361-Genetic Vectors,
pubmed-meshheading:16874361-Humans,
pubmed-meshheading:16874361-Inflammation,
pubmed-meshheading:16874361-Mice,
pubmed-meshheading:16874361-Mice, Inbred C57BL,
pubmed-meshheading:16874361-Mice, Transgenic,
pubmed-meshheading:16874361-Neoplasms,
pubmed-meshheading:16874361-Recoverin,
pubmed-meshheading:16874361-Tissue Distribution,
pubmed-meshheading:16874361-Uterine Cervical Neoplasms
|
|
pubmed:year |
2006
|
|
pubmed:articleTitle |
Evaluation of adenovirus vectors containing serotype 35 fibers for tumor targeting.
|
|
pubmed:affiliation |
Division of Medical Genetics, Department of Medicine, University of Washington, Seattle, WA 98195, USA.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Research Support, N.I.H., Extramural
|
